Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants
Sponsor: Regeneron Pharmaceuticals
Summary
This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined by age, sex, race, and ethnicity. Participants will be retrospectively identified from at least two US Electronic Health Record (EHR)-based databases.
Official title: Evaluating the Safety and Effectiveness of Cemiplimab in Combination With Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multi-Database Real World Evidence Study in US Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2024-02-21
Completion Date
2027-03-31
Last Updated
2026-09-10
Healthy Volunteers
No
Conditions
Interventions
REGN2810
No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.
Platinum-doublet chemotherapy
No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.
Locations (1)
Regeneron Research Facility
Tarrytown, New York, United States